The emerging role of Interleukin 37 in bone homeostasis and inflammatory bone diseases
•Interleukin 37 (IL-37) is a new member of the IL-1 family, which broadly reduces innate inflammation as well as acquired immune responses.•IL-37 plays an anti-inflammatory role as a dual cytokine with both intra- and extra-cellular functions.•IL-37 can inhibit osteoclast differentiation directly an...
Gespeichert in:
| Veröffentlicht in: | International immunopharmacology 2021-09, Vol.98, p.107803-107803, Article 107803 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 107803 |
|---|---|
| container_issue | |
| container_start_page | 107803 |
| container_title | International immunopharmacology |
| container_volume | 98 |
| creator | Wu, Peiyao Zhou, Jieyu Wu, Yafei Zhao, Lei |
| description | •Interleukin 37 (IL-37) is a new member of the IL-1 family, which broadly reduces innate inflammation as well as acquired immune responses.•IL-37 plays an anti-inflammatory role as a dual cytokine with both intra- and extra-cellular functions.•IL-37 can inhibit osteoclast differentiation directly and indirectly and promote osteogenic differentiation of bone marrow mesenchymal stem cells.•The levels of IL-37 were abnormal in patients with inflammatory bone diseases.•In vivo studies have confirmed that recombinant IL-37 treatment displayed therapeutic potential in inflammatory bone diseases.
Interleukin 37 (IL-37) is a newly identified cytokine that belongs to the IL-1 family. Unlike other members of the IL-1 family, it has been demonstrated that IL-37 possesses anti-inflammatory characteristics in both innate and acquired immune responses. Recently, significant progress has been made in understanding the role of IL-37 in inflammatory signaling pathways. Meanwhile, IL-37 has also attracted more and more attention in bone homeostasis and inflammatory bone diseases. The latest studies have revealed that IL-37 palys an essential role in the regulation of osteoclastogenesis and osteoblastogenesis. The levels of IL-37 are abnormal in patients with inflammatory bone diseases such as rheumatoid arthritis (RA), osteoarthritis (OA), ankylosing spondylitis (AS), and periodontitis. In addition, in vivo studies have further confirmed that recombinant IL-37 treatment displayed therapeutic potential in these diseases. The present review article aims to provide an overview describing the biological functions of IL-37 in bone homeostasis and inflammatory bone diseases, thus shedding new light on a novel therapeutic strategy in the future. |
| doi_str_mv | 10.1016/j.intimp.2021.107803 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2538046769</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1567576921004392</els_id><sourcerecordid>2574803084</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-579f2b681eea420dbd1c773bb6595cff6f1282a2f8a90103b62794f4151dcb903</originalsourceid><addsrcrecordid>eNp9kE1LxDAQhoMorq7-A5GCFy-7JmnStBdBFj8WFryo15Cmk92sbbImreC_N1L14MHLZHh5ZjI8CJ0RPCeYFFfbuXW97XZziilJkShxvoeOSCnKGRGY76eeF2LGRVFN0HGMW4xTzsghmuQMV4RyfoRenjaQQQdhbd06C76FzJts6XoILQyv1mW5yFKtvYNs4zvwsVfRxky5JuWmVV2neh8-RqKxEVSEeIIOjGojnH6_U_R8d_u0eJitHu-Xi5vVTOcV7tNtlaF1URIAxShu6oZoIfK6LnjFtTGFIbSkippSVZjgvC6oqJhhhJNG1xXOp-hy3LsL_m2A2MvORg1tqxz4IUrK8xKzIilI6MUfdOuH4NJ1iRIs2cMlSxQbKR18jAGM3AXbqfAhCZZf3uVWjt7ll3c5ek9j59_Lh7qD5nfoR3QCrkcAko13C0FGbcFpaGwA3cvG2_9_-AR6XJR_</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2574803084</pqid></control><display><type>article</type><title>The emerging role of Interleukin 37 in bone homeostasis and inflammatory bone diseases</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Wu, Peiyao ; Zhou, Jieyu ; Wu, Yafei ; Zhao, Lei</creator><creatorcontrib>Wu, Peiyao ; Zhou, Jieyu ; Wu, Yafei ; Zhao, Lei</creatorcontrib><description>•Interleukin 37 (IL-37) is a new member of the IL-1 family, which broadly reduces innate inflammation as well as acquired immune responses.•IL-37 plays an anti-inflammatory role as a dual cytokine with both intra- and extra-cellular functions.•IL-37 can inhibit osteoclast differentiation directly and indirectly and promote osteogenic differentiation of bone marrow mesenchymal stem cells.•The levels of IL-37 were abnormal in patients with inflammatory bone diseases.•In vivo studies have confirmed that recombinant IL-37 treatment displayed therapeutic potential in inflammatory bone diseases.
Interleukin 37 (IL-37) is a newly identified cytokine that belongs to the IL-1 family. Unlike other members of the IL-1 family, it has been demonstrated that IL-37 possesses anti-inflammatory characteristics in both innate and acquired immune responses. Recently, significant progress has been made in understanding the role of IL-37 in inflammatory signaling pathways. Meanwhile, IL-37 has also attracted more and more attention in bone homeostasis and inflammatory bone diseases. The latest studies have revealed that IL-37 palys an essential role in the regulation of osteoclastogenesis and osteoblastogenesis. The levels of IL-37 are abnormal in patients with inflammatory bone diseases such as rheumatoid arthritis (RA), osteoarthritis (OA), ankylosing spondylitis (AS), and periodontitis. In addition, in vivo studies have further confirmed that recombinant IL-37 treatment displayed therapeutic potential in these diseases. The present review article aims to provide an overview describing the biological functions of IL-37 in bone homeostasis and inflammatory bone diseases, thus shedding new light on a novel therapeutic strategy in the future.</description><identifier>ISSN: 1567-5769</identifier><identifier>EISSN: 1878-1705</identifier><identifier>DOI: 10.1016/j.intimp.2021.107803</identifier><identifier>PMID: 34091255</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Animals ; Ankylosing spondylitis ; Arthritis ; Arthritis, Rheumatoid - drug therapy ; Arthritis, Rheumatoid - immunology ; Arthritis, Rheumatoid - pathology ; Biomedical materials ; Bone and Bones - drug effects ; Bone and Bones - immunology ; Bone and Bones - pathology ; Bone diseases ; Bone homeostasis ; Bone turnover ; Cell Differentiation - drug effects ; Cell Differentiation - immunology ; Cytokines ; Disease Models, Animal ; Homeostasis ; Humans ; IL-37 ; Immune response ; In vivo methods and tests ; Interleukin 1 ; Interleukin-1 - metabolism ; Interleukin-1 - therapeutic use ; Mesenchymal Stem Cells ; Osteoarthritis ; Osteoarthritis - drug therapy ; Osteoarthritis - immunology ; Osteoarthritis - pathology ; Osteoblastogenesis ; Osteoclastogenesis ; Osteogenesis - drug effects ; Osteogenesis - immunology ; Periodontitis ; Periodontitis - drug therapy ; Periodontitis - immunology ; Periodontitis - pathology ; Recombinant Proteins - metabolism ; Recombinant Proteins - therapeutic use ; Rheumatoid arthritis ; Spondylitis, Ankylosing - drug therapy ; Spondylitis, Ankylosing - immunology ; Spondylitis, Ankylosing - pathology</subject><ispartof>International immunopharmacology, 2021-09, Vol.98, p.107803-107803, Article 107803</ispartof><rights>2021 Elsevier B.V.</rights><rights>Copyright © 2021 Elsevier B.V. All rights reserved.</rights><rights>Copyright Elsevier BV Sep 2021</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-579f2b681eea420dbd1c773bb6595cff6f1282a2f8a90103b62794f4151dcb903</citedby><cites>FETCH-LOGICAL-c390t-579f2b681eea420dbd1c773bb6595cff6f1282a2f8a90103b62794f4151dcb903</cites><orcidid>0000-0003-3978-7165 ; 0000-0002-9612-3114</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1567576921004392$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34091255$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wu, Peiyao</creatorcontrib><creatorcontrib>Zhou, Jieyu</creatorcontrib><creatorcontrib>Wu, Yafei</creatorcontrib><creatorcontrib>Zhao, Lei</creatorcontrib><title>The emerging role of Interleukin 37 in bone homeostasis and inflammatory bone diseases</title><title>International immunopharmacology</title><addtitle>Int Immunopharmacol</addtitle><description>•Interleukin 37 (IL-37) is a new member of the IL-1 family, which broadly reduces innate inflammation as well as acquired immune responses.•IL-37 plays an anti-inflammatory role as a dual cytokine with both intra- and extra-cellular functions.•IL-37 can inhibit osteoclast differentiation directly and indirectly and promote osteogenic differentiation of bone marrow mesenchymal stem cells.•The levels of IL-37 were abnormal in patients with inflammatory bone diseases.•In vivo studies have confirmed that recombinant IL-37 treatment displayed therapeutic potential in inflammatory bone diseases.
Interleukin 37 (IL-37) is a newly identified cytokine that belongs to the IL-1 family. Unlike other members of the IL-1 family, it has been demonstrated that IL-37 possesses anti-inflammatory characteristics in both innate and acquired immune responses. Recently, significant progress has been made in understanding the role of IL-37 in inflammatory signaling pathways. Meanwhile, IL-37 has also attracted more and more attention in bone homeostasis and inflammatory bone diseases. The latest studies have revealed that IL-37 palys an essential role in the regulation of osteoclastogenesis and osteoblastogenesis. The levels of IL-37 are abnormal in patients with inflammatory bone diseases such as rheumatoid arthritis (RA), osteoarthritis (OA), ankylosing spondylitis (AS), and periodontitis. In addition, in vivo studies have further confirmed that recombinant IL-37 treatment displayed therapeutic potential in these diseases. The present review article aims to provide an overview describing the biological functions of IL-37 in bone homeostasis and inflammatory bone diseases, thus shedding new light on a novel therapeutic strategy in the future.</description><subject>Animals</subject><subject>Ankylosing spondylitis</subject><subject>Arthritis</subject><subject>Arthritis, Rheumatoid - drug therapy</subject><subject>Arthritis, Rheumatoid - immunology</subject><subject>Arthritis, Rheumatoid - pathology</subject><subject>Biomedical materials</subject><subject>Bone and Bones - drug effects</subject><subject>Bone and Bones - immunology</subject><subject>Bone and Bones - pathology</subject><subject>Bone diseases</subject><subject>Bone homeostasis</subject><subject>Bone turnover</subject><subject>Cell Differentiation - drug effects</subject><subject>Cell Differentiation - immunology</subject><subject>Cytokines</subject><subject>Disease Models, Animal</subject><subject>Homeostasis</subject><subject>Humans</subject><subject>IL-37</subject><subject>Immune response</subject><subject>In vivo methods and tests</subject><subject>Interleukin 1</subject><subject>Interleukin-1 - metabolism</subject><subject>Interleukin-1 - therapeutic use</subject><subject>Mesenchymal Stem Cells</subject><subject>Osteoarthritis</subject><subject>Osteoarthritis - drug therapy</subject><subject>Osteoarthritis - immunology</subject><subject>Osteoarthritis - pathology</subject><subject>Osteoblastogenesis</subject><subject>Osteoclastogenesis</subject><subject>Osteogenesis - drug effects</subject><subject>Osteogenesis - immunology</subject><subject>Periodontitis</subject><subject>Periodontitis - drug therapy</subject><subject>Periodontitis - immunology</subject><subject>Periodontitis - pathology</subject><subject>Recombinant Proteins - metabolism</subject><subject>Recombinant Proteins - therapeutic use</subject><subject>Rheumatoid arthritis</subject><subject>Spondylitis, Ankylosing - drug therapy</subject><subject>Spondylitis, Ankylosing - immunology</subject><subject>Spondylitis, Ankylosing - pathology</subject><issn>1567-5769</issn><issn>1878-1705</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1LxDAQhoMorq7-A5GCFy-7JmnStBdBFj8WFryo15Cmk92sbbImreC_N1L14MHLZHh5ZjI8CJ0RPCeYFFfbuXW97XZziilJkShxvoeOSCnKGRGY76eeF2LGRVFN0HGMW4xTzsghmuQMV4RyfoRenjaQQQdhbd06C76FzJts6XoILQyv1mW5yFKtvYNs4zvwsVfRxky5JuWmVV2neh8-RqKxEVSEeIIOjGojnH6_U_R8d_u0eJitHu-Xi5vVTOcV7tNtlaF1URIAxShu6oZoIfK6LnjFtTGFIbSkippSVZjgvC6oqJhhhJNG1xXOp-hy3LsL_m2A2MvORg1tqxz4IUrK8xKzIilI6MUfdOuH4NJ1iRIs2cMlSxQbKR18jAGM3AXbqfAhCZZf3uVWjt7ll3c5ek9j59_Lh7qD5nfoR3QCrkcAko13C0FGbcFpaGwA3cvG2_9_-AR6XJR_</recordid><startdate>202109</startdate><enddate>202109</enddate><creator>Wu, Peiyao</creator><creator>Zhou, Jieyu</creator><creator>Wu, Yafei</creator><creator>Zhao, Lei</creator><general>Elsevier B.V</general><general>Elsevier BV</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T5</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3978-7165</orcidid><orcidid>https://orcid.org/0000-0002-9612-3114</orcidid></search><sort><creationdate>202109</creationdate><title>The emerging role of Interleukin 37 in bone homeostasis and inflammatory bone diseases</title><author>Wu, Peiyao ; Zhou, Jieyu ; Wu, Yafei ; Zhao, Lei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-579f2b681eea420dbd1c773bb6595cff6f1282a2f8a90103b62794f4151dcb903</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Animals</topic><topic>Ankylosing spondylitis</topic><topic>Arthritis</topic><topic>Arthritis, Rheumatoid - drug therapy</topic><topic>Arthritis, Rheumatoid - immunology</topic><topic>Arthritis, Rheumatoid - pathology</topic><topic>Biomedical materials</topic><topic>Bone and Bones - drug effects</topic><topic>Bone and Bones - immunology</topic><topic>Bone and Bones - pathology</topic><topic>Bone diseases</topic><topic>Bone homeostasis</topic><topic>Bone turnover</topic><topic>Cell Differentiation - drug effects</topic><topic>Cell Differentiation - immunology</topic><topic>Cytokines</topic><topic>Disease Models, Animal</topic><topic>Homeostasis</topic><topic>Humans</topic><topic>IL-37</topic><topic>Immune response</topic><topic>In vivo methods and tests</topic><topic>Interleukin 1</topic><topic>Interleukin-1 - metabolism</topic><topic>Interleukin-1 - therapeutic use</topic><topic>Mesenchymal Stem Cells</topic><topic>Osteoarthritis</topic><topic>Osteoarthritis - drug therapy</topic><topic>Osteoarthritis - immunology</topic><topic>Osteoarthritis - pathology</topic><topic>Osteoblastogenesis</topic><topic>Osteoclastogenesis</topic><topic>Osteogenesis - drug effects</topic><topic>Osteogenesis - immunology</topic><topic>Periodontitis</topic><topic>Periodontitis - drug therapy</topic><topic>Periodontitis - immunology</topic><topic>Periodontitis - pathology</topic><topic>Recombinant Proteins - metabolism</topic><topic>Recombinant Proteins - therapeutic use</topic><topic>Rheumatoid arthritis</topic><topic>Spondylitis, Ankylosing - drug therapy</topic><topic>Spondylitis, Ankylosing - immunology</topic><topic>Spondylitis, Ankylosing - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wu, Peiyao</creatorcontrib><creatorcontrib>Zhou, Jieyu</creatorcontrib><creatorcontrib>Wu, Yafei</creatorcontrib><creatorcontrib>Zhao, Lei</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>International immunopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wu, Peiyao</au><au>Zhou, Jieyu</au><au>Wu, Yafei</au><au>Zhao, Lei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The emerging role of Interleukin 37 in bone homeostasis and inflammatory bone diseases</atitle><jtitle>International immunopharmacology</jtitle><addtitle>Int Immunopharmacol</addtitle><date>2021-09</date><risdate>2021</risdate><volume>98</volume><spage>107803</spage><epage>107803</epage><pages>107803-107803</pages><artnum>107803</artnum><issn>1567-5769</issn><eissn>1878-1705</eissn><abstract>•Interleukin 37 (IL-37) is a new member of the IL-1 family, which broadly reduces innate inflammation as well as acquired immune responses.•IL-37 plays an anti-inflammatory role as a dual cytokine with both intra- and extra-cellular functions.•IL-37 can inhibit osteoclast differentiation directly and indirectly and promote osteogenic differentiation of bone marrow mesenchymal stem cells.•The levels of IL-37 were abnormal in patients with inflammatory bone diseases.•In vivo studies have confirmed that recombinant IL-37 treatment displayed therapeutic potential in inflammatory bone diseases.
Interleukin 37 (IL-37) is a newly identified cytokine that belongs to the IL-1 family. Unlike other members of the IL-1 family, it has been demonstrated that IL-37 possesses anti-inflammatory characteristics in both innate and acquired immune responses. Recently, significant progress has been made in understanding the role of IL-37 in inflammatory signaling pathways. Meanwhile, IL-37 has also attracted more and more attention in bone homeostasis and inflammatory bone diseases. The latest studies have revealed that IL-37 palys an essential role in the regulation of osteoclastogenesis and osteoblastogenesis. The levels of IL-37 are abnormal in patients with inflammatory bone diseases such as rheumatoid arthritis (RA), osteoarthritis (OA), ankylosing spondylitis (AS), and periodontitis. In addition, in vivo studies have further confirmed that recombinant IL-37 treatment displayed therapeutic potential in these diseases. The present review article aims to provide an overview describing the biological functions of IL-37 in bone homeostasis and inflammatory bone diseases, thus shedding new light on a novel therapeutic strategy in the future.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>34091255</pmid><doi>10.1016/j.intimp.2021.107803</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0003-3978-7165</orcidid><orcidid>https://orcid.org/0000-0002-9612-3114</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1567-5769 |
| ispartof | International immunopharmacology, 2021-09, Vol.98, p.107803-107803, Article 107803 |
| issn | 1567-5769 1878-1705 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2538046769 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Animals Ankylosing spondylitis Arthritis Arthritis, Rheumatoid - drug therapy Arthritis, Rheumatoid - immunology Arthritis, Rheumatoid - pathology Biomedical materials Bone and Bones - drug effects Bone and Bones - immunology Bone and Bones - pathology Bone diseases Bone homeostasis Bone turnover Cell Differentiation - drug effects Cell Differentiation - immunology Cytokines Disease Models, Animal Homeostasis Humans IL-37 Immune response In vivo methods and tests Interleukin 1 Interleukin-1 - metabolism Interleukin-1 - therapeutic use Mesenchymal Stem Cells Osteoarthritis Osteoarthritis - drug therapy Osteoarthritis - immunology Osteoarthritis - pathology Osteoblastogenesis Osteoclastogenesis Osteogenesis - drug effects Osteogenesis - immunology Periodontitis Periodontitis - drug therapy Periodontitis - immunology Periodontitis - pathology Recombinant Proteins - metabolism Recombinant Proteins - therapeutic use Rheumatoid arthritis Spondylitis, Ankylosing - drug therapy Spondylitis, Ankylosing - immunology Spondylitis, Ankylosing - pathology |
| title | The emerging role of Interleukin 37 in bone homeostasis and inflammatory bone diseases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T18%3A03%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20emerging%20role%20of%20Interleukin%2037%20in%20bone%20homeostasis%20and%20inflammatory%20bone%20diseases&rft.jtitle=International%20immunopharmacology&rft.au=Wu,%20Peiyao&rft.date=2021-09&rft.volume=98&rft.spage=107803&rft.epage=107803&rft.pages=107803-107803&rft.artnum=107803&rft.issn=1567-5769&rft.eissn=1878-1705&rft_id=info:doi/10.1016/j.intimp.2021.107803&rft_dat=%3Cproquest_cross%3E2574803084%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2574803084&rft_id=info:pmid/34091255&rft_els_id=S1567576921004392&rfr_iscdi=true |